The Dawson James Small Cap Growth Conference will be held at the Wyndham Grand Hotel, Jupiter FL. The event will showcase discussions, presentations, and keynotes by 30 senior management teams and industry leaders on the latest developments and exciting opportunities in the small-cap segment.
For more information visit:
Conference Website
- 22nd Century Group, Inc.
- Amergent Hospitality Group Inc.
- Bruush Oral Care Inc.
- Cemtrex Inc.
- Charge Enterprises Inc.
- Charlie's Holdings, Inc.
- Citius Pharmaceuticals, Inc.
- Cocrystal Pharma
- CollPlant Biotechnologies
- CytoSorbents Corporation
- Fresh Vine Wine, Inc.
- GBS, Inc.
22nd Century Group, Inc. (NASDAQ: XXII)
22nd Century Group, Inc. (NASDAQ: XXII) is a leading plant biotechnology and intellectual property company focused on improving health and wellness through plant science. 22nd Century uses modern plant breeding technologies, gene-editing, and molecular breeding to deliver value to its customers in the life science and consumer products industries by creating new, proprietary tobacco, hemp/cannabis and hop plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits. 22nd Century was founded to build intellectual property related to nicotine biosynthesis in the tobacco plant and to commercialize its proprietary reduced nicotine content (RNC) tobacco plants, which have become the cornerstone of FDA's comprehensive plan to address the enormous amount of death and disease caused by addiction to smoking. The Company has also begun to leverage its plant science expertise and existing partnerships to create and commercialize new, proprietary hemp/cannabis and hop plants to optimize their genetics and create valuable new intellectual property. For more information, visit the company's website at: www.xxiicentury.com
Amergent Hospitality Group Inc. (OTCQB: AMHG)
Amergent Hospitality Group Inc. (OTCQB: AMHG) headquartered in Charlotte, NC, Amergent owns, operates, and franchises fast, casual, and full-service restaurant brands, including American Burger Company, BGR - Burgers Grilled Right, Little Big Burger, PizzaRev, and Hooters gaming venue. For more information, visit the company's website at: www.amergenthg.com
Bruush Oral Care Inc. (NASDAQ: BRSH)
Bruush Oral Care Inc. (NASDAQ:BRSH) is on a mission to inspire confidence through brighter smiles and better oral health. Founded in 2018, Brüush is an oral care company that is disrupting the space by reducing the barriers between consumers and access to premium oral care products. The Company is an e-commerce business with a product portfolio that currently consists of a sonic-powered electric toothbrush kit and brush head refills. Brüush has developed a product to make upgrading to an electric brush appealing with three core priorities in mind: (i) a high-quality electric toothbrush at a more affordable price than a comparable electric toothbrush from the competition; (ii) a sleek, countertop-friendly design; and (iii) a convenient brush head refill subscription program that eliminates the frustrating experience of purchasing replacement brush heads at the grocery/drug store. The Company is rooted in building a brand that creates relevant experiences and content, with the goal of becoming the go-to oral care brand for millennials and Generation Z. For more information, visit the company's website at: bruush.com
Cemtrex Inc. (NASDAQ: CETX) (NASDAQ: CETXP)
Cemtrex Inc. (NASDAQ: CETX) (NASDAQ: CETXP) is a leading multi-industry technology company that is driving innovation in markets such as Internet of Things (IoT), Augmented and Virtual Reality (AR & VR), and Artificial Intelligence and Computer Vision (AI & CV) in a wide range of sectors, including but not limited to consumer products, industrial manufacturing, digital applications, and intelligent security & surveillance systems. For more information, visit the company's website at: www.cemtrex.com
Charge Enterprises Inc. (OTC: CRGE)
Charge Enterprises Inc. (OTC: CRGE) has a mission of connecting people everywhere with a strategy that incorporates telecom network infrastructure, connected calls, power banks and charging for electric vehicles. Trading on the OTC with an application recently submitted to the Nasdaq for uplisting, Charge Enterprises is a public company that shares its success with all stakeholders. The company operates in three distinct divisions through a number of recently acquired, or newly formed subsidiaries, including Charge Communications, Chare Infrastructure, Charge Investment and ANS Advanced Network Services. The management team is focused on the unglamorous part of connecting calls and powering the future of movement. For more information, visit the company's website at: www.charge.us
Charlie's Holdings, Inc. (OTCQB: CHUC)
Charlie's Holdings, Inc. (OTCQB:CHUC) is an industry leader in the premium, nicotine-based, vapor products space. The Company's products are sold around the world to select distributors, specialty retailers, and third-party online resellers through subsidiary companies Charlie's Chalk Dust, LLC and Don Polly, LLC. Charlie's Chalk Dust, LLC has developed an extensive portfolio of brand styles, flavor profiles, and innovative product formats. Don Polly, LLC creates innovative hemp-derived products and brands. For more information, visit the company's website at: CharliesHoldings.com
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company has two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), which has completed subject treatment in its Pivotal Phase 3 trial. Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on acute respiratory distress syndrome (ARDS). For more information visit the company's website at: www.citiuspharma.com
Cocrystal Pharma (NASDAQ: COCP)
Cocrystal Pharma, Inc. (NASDAQ: COCP) is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For more information, visit the company's website at: www.cocrystalpharma.com
CollPlant Biotechnologies (NASDAQ: CLGN)
CollPlant Biotechnologies (NASDAQ: CLGN) is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine. At the beginning of 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. Later in 2021, CollPlant entered a strategic co-development agreement with 3D Systems for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant. For more information, visit the company's website at: www.collplant.com
CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb®, is approved in the European Union and distributed in more than 70 countries worldwide. It is an extracorporeal cytokine adsorber that reduces "cytokine storm" or "cytokine release syndrome" in common critical illnesses that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to postoperative complications, including multiple organ failure. As of June 30, 2022, more than 179,000 CytoSorb devices have been used cumulatively. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. For more information, visit the company's website at: www.cytosorbents.com
Fresh Vine Wine, Inc. (NYSE American: VINE)
Fresh Vine Wine, Inc. (NYSE American: VINE) is a premier producer of lower carb, lower calorie premium wines in the United States, kicking off a 2022 growth plan following its IPO in mid-December 2021. Fresh Vine Wine's brand vision is to lead the emerging natural and accessible premium wine category, as health trends continue to accelerate in the US marketplace. The 2020 US wine market was a $69 billion category. Fresh Vine Wine plans to accelerate growth in 2022 by amplifying its marketing, expanding product offerings, and expanding its team. Fresh Vine Wine positions its core brand lineup as an affordable luxury, retailing between $14.99-$22.99. Fresh Vine Wine's varietals currently include its Cabernet Sauvignon, Chardonnay, Pinot Noir, and Rosé. For more information, visit the company's website at: www.freshvinewine.com
GBS, Inc. (NASDAQ: GBS)
GBS, Inc. (NASDAQ: GBS) is on a mission to put the power of non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help eradicate COVID-19 and change the lives of people living with diabetes. For more information, visit the company's website at: www.gbs.inc
Genius Brands International, Inc. (NASDAQ: GNUS)
Genius Brands International, Inc. (NASDAQ: GNUS) is a leading global kids media company developing, producing, marketing and licensing branded children's entertainment properties and consumer products for media and retail distribution. The Company's 'content with a purpose' portfolio includes Stan Lee's Superhero Kindergarten, starring Arnold Schwarzenegger, on Kartoon Channel!; Shaq's Garage, starring Shaquille O'Neal on Kartoon Channel!; Rainbow Rangers on Kartoon Channel! and Netflix; Llama Llama, starring Jennifer Garner, on Netflix; award-winning toddler brand Baby Genius; adventure comedy STEM series Thomas Edison's Secret Lab; and entrepreneurship series Warren Buffett's Secret Millionaires Club. Through licensing agreements with leading partners, characters from Genius Brands' IP also appear on a wide range of consumer products for the worldwide retail marketplace. The Company's Kartoon Channel! and Kartoon Classroom! are available in over 100 million U.S. television households via a broad range of distribution platforms, including Comcast, Cox, DISH, Sling TV, Amazon Prime, Amazon Fire, Apple TV, Apple iOS, Android TV, Android Mobil, Google Play, Xumo, Roku, Tubi, YouTube, KartoonChannel.com, Samsung Smart TVs and LG TVs. For more information, visit the company's website at: www.gnusbrands.com
Genprex, Inc. (NASDAQ: GNPX)
Genprex, Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is then taken up by tumor cells that express tumor suppressor proteins that are deficient in the body. The Company's lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC) (with each of these clinical programs receiving a Fast Track Designation from the Food and Drug Administration) and for small cell lung cancer. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas. In models of T1D, the genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system. For more information, visit the company's website at: www.genprex.com
Greenwave Technology Solutions, Inc. (NASDAQ: GWAV)
Greenwave Technology Solutions, Inc. (NASDAQ: GWAV) through its wholly owned subsidiary Empire Services, Inc. ("Empire"), is a leading operator of 11 metal recycling facilities in Virginia and North Carolina. At these facilities, Empire collects, classifies, and processes raw scrap metal (ferrous and nonferrous) for recycling. Steel is one of the world's most recycled products with the ability to be re-melted and recast numerous times while offering significant economic and environmental benefits when compared with virgin materials. For more information, visit the company's website at: www.greenwavetechnologysolutions.com
HeartBeam, Inc. (NASDAQ: BEAT)
HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital healthcare company with proprietary ECG telemedicine technology that will redefine the way high risk cardiovascular patients are diagnosed in an ambulatory setting at any time and any place. Its breakthrough solution employs a reusable, credit card sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease. HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and their physicians. This underserved market is several times larger than the cardiac arrhythmia detection market based on the prevalence of patients with coronary artery disease at high risk of heart attack. For more information, visit the company's website at: www.heartbeam.com
Hillstream BioPharma, Inc. (NASDAQ: HILS)
Hillstream BioPharma, Inc. (NASDAQ: HILS) is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers. Hillstream's most advanced candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The active drug in HSB-1216 was found to be efficacious in a clinical pilot study in Germany in devastating cancers, including triple negative breast cancer and epithelial carcinomas. Hillstream intends to start a clinical study with HSB-1216 in 2022 to expand upon the existing early clinical proof-of-concept. Hillstream uses Quatramer™, their proprietary tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment with an extended duration of action and minimal off-target toxicity. In addition, Trident Artificial Intelligence, Hillstream's artificial intelligence precision medicine platform, is used to identify biomarkers in their clinical programs to target a specific patient segment most likely to benefit. For more information, visit the company's website at: www.hillstreambio.com
Iconic Brands, Inc. (OTC: ICNB)
Iconic Brands, Inc. (OTC: ICNB) is a leader in the development, design and delivery of alcohol and non-alcohol beverages. TopPop, Iconic's wholly owned subsidiary, is a leader in the innovation of low-calorie, "ready to go" drinks and ready-to-freeze (RTF) and ready-to-drink (RTD) products in sustainable, flexible and stand-up pouch packaging, and in the alcohol ice-pop and "cocktails-to-go" market. Iconic's brands include "Bellissima" by Christie Brinkley, a premium better-for-you and better-for-the-planet collection of prosecco, sparkling wines and still wines, all of which are certified vegan and made with organic grapes. Bellissima is strategically positioned with its zero sugar wines in the zero sugar beverage category. Iconic operates in multiple states, distributes around the globe and has Fortune 500 customers that include some of the world's largest alcohol beverage companies and brands. For more information, visit the company's website at: www.iconicbrandsusa.com
Laredo Oil, Inc. (OTC: LRDC)
Laredo Oil, Inc. (OTC Pink Sheets: LRDC) is an oil exploration and production company primarily engaged in acquisition and exploration efforts for mineral properties. In addition to pursuing conventional oil recovery methods in selected oil fields, Laredo Oil plans to locate and acquire mature oil fields, with the intention of recovering "stranded" oil using enhanced recovery methods. Laredo Oil's common stock is listed on the OTC Pink Sheets under the symbol "LRDC." For more information, visit the company's website at: www.laredo-oil.com
Longeveron Inc. (NASDAQ: LGVN)
Longeveron Inc. (NASDAQ: LGVN) is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B™ cell-based therapy product ("Lomecel-B"), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer's disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company's mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization, and broad use by the healthcare community. For more information, visit the company's website at: www.longeveron.com
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD)
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit the company's website at: www.mymd.com
NEXGEL, Inc. (NASDAQ: NXGL) (NASDAQ: NXGLW)
NEXGEL, Inc. (NASDAQ: NXGL) (NASDAQ: NXGLW) is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation. For more information, visit the company's website at: nexgel.com
NextPlat Corp (NASDAQ: NXPL) (NASDAQ: NXPLW)
NextPlat Corp (NASDAQ: NXPL) (NASDAQ: NXPLW) is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets for physical and digital assets. The Company intends to collaborate with businesses, optimizing their ability to sell their goods online, domestically, and internationally, and enabling customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications services division through its Global Telesat Communications Ltd and Orbital Satcom Corp business units that offer voice, data, tracking, and IoT services to customers worldwide through multiple global storefronts. For more information, visit the company's website at: nextplat.com
OS Therapies Inc.
OS Therapies Inc. is a research and clinical-stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other deadly cancers in kids and adults. OS Therapies has two platform technologies being developed for therapies to treat and cure Osteosarcoma (OS) and other solid tumors including ovarian, esophageal, endometrial and lung cancers. For more information, visit the company's website at: www.ostherapies.com
Profire Energy, Inc. (NASDAQ: PFIE)
Profire Energy, Inc. (NASDAQ: PFIE) assists energy production companies in the safe and efficient production and transportation of oil and natural gas. As energy companies seek greater safety for their employees, compliance with more stringent regulatory standards, and enhanced margins with their energy production processes, Profire Energy's burner management and chemical injection products are continuing to be a key part of their solutions. Profire Energy has offices in Lindon, Utah; Victoria, Texas; Homer, Pennsylvania; Greeley, Colorado; Millersburg, Ohio; and Spruce Grove, Alberta, Canada. For more information visit the company's website at: www.profireenergy.com
Safe-T Group Ltd. (NASDAQ: SFET)
Safe-T Group Ltd. (NASDAQ: SFET) is a global provider of cyber-security and privacy solutions to consumers and enterprises. The Company operates in three distinct segments, tailoring solutions according to specific needs. The segments include, enterprise cyber-security solutions, enterprise privacy solutions, and consumer cyber-security and privacy solutions. For more information, visit the company's website at: www.safetgroup.com
Silo Pharma, Inc. (OTCQB: SILO)
Silo Pharma, Inc. (OTCQB: SILO) is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson's, and other rare neurological disorders. Silo's mission is to identify assets to license and fund the research which they believe will be transformative to the well-being of patients and the healthcare industry. For more information, information, visit the company's website at: www.silopharma.com
Smith Micro Software, Inc. (NASDAQ: SMSI)
Smith Micro Software, Inc. (NASDAQ: SMSI) develops software to simplify and enhance the mobile experience, providing solutions to some of the leading wireless service providers and cable MSOs around the world. From enabling the family digital lifestyle to providing powerful voice messaging capabilities, their solutions enrich today's connected lifestyles while creating new opportunities to engage consumers via smartphones and consumer IoT devices. The Smith Micro portfolio also includes a wide range of products for creating, sharing and monetizing rich content, such as visual voice messaging, optimizing retail content display and performing analytics on any product set. For more information visit the company's website at: www.smithmicro.com
Splash Beverage Group (NYSE: SBEV)
Splash Beverage Group (NYSE: SBEV) an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wine by the glass, SALT flavored tequilas, Pulpoloco sangria, and TapouT performance hydration and recovery drink. Splash's strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution. For more information visit the company's website at: www.SplashBeverageGroup.com
SRAX (NASDAQ: SRAX)
SRAX (NASDAQ: SRAX) is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors' behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information, visit the company's website at: srax.com
TC Biopharm PLC (NASDAQ: TCBP) (NASDAQ: TCBPW)
TC Biopharm PLC (NASDAQ: TCBP) (NASDAQ: TCBPW) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma delta t-cells to effectively identify, target and eradicate both liquid and solid tumors in cancer. TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia and Phase I trial for ImmuniStim in treatment of Covid patients using the Company's proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide. TC BioPharm also maintains a robust pipeline for future indications in solid tumors and a significant IP/patent portfolio in the use of CARs with gamma delta t-cells and owns their manufacturing facility to maintain cost and product quality controls.
VolitionRx Limited (NYSE AMERICAN: VNRX)
VolitionRx Limited (NYSE AMERICAN: VNRX) is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid—an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring, but also has a subsidiary focused on animal diagnostics and monitoring. Volition's research and development activities are centered in Belgium, with an innovation laboratory and an office in the U.S. and additional offices in London and Singapore. For more information visit the company's website at: volition.com
Vuzix Corp. (NASDAQ: VUZI)
Vuzix Corp. (NASDAQ: VUZI) is a leading supplier of Smart Glasses and Augmented Reality (AR) technologies and products for the consumer and enterprise markets. The Company's products include personal display and wearable computing devices that offer users a portable high-quality viewing experience, provide solutions for mobility, wearable displays and augmented reality. Vuzix holds 244 patents and patents pending and numerous IP licenses in the Video Eyewear field. The Company has won Consumer Electronics Show (or CES) awards for innovation for the years 2005 to 2022 and several wireless technology innovation awards among others. Founded in 1997, Vuzix is a public company (NASDAQ: VUZI) with offices in Rochester, NY, Oxford, UK, and Tokyo, Japan. For more information, visit the company's website at: www.Vuzix.com
Zerify, Inc. (OCTQB: ZRFY)
Zerify, Inc. (OCTQB: ZRFY), formerly StrikeForce Technologies, helps to prevent cyber theft and data security breaches for consumers, corporations, and government agencies. It provides powerful two-factor, "out-of-band" authentication and keystroke encryption along with mobile solutions. Zerify is headquartered in Edison, N.J. . For more information, visit the company's website at: www.zerify.com
Zomedica Corp. (NYSE American: ZOM)
Zomedica (NYSE American: ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit the company's website: www.ZOMEDICA.com